Amgen, Merck To Test New Immunotherapy Combination
This article was originally published in Scrip
Executive Summary
Amgen Inc. and Merck & Co. Inc. inked a collaboration agreement to test their antibody therapies Blincyto (blinatumomab) and Keytruda (pembrolizumab) in patients with diffuse large B-Cell lymphoma (DLBCL) in a Phase Ib/III clinical trial.
You may also be interested in...
Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.